# Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients?

> **NCT01837745** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 776 (actual)

## Conditions studied

- Low Risk Differentiated Thyroid Cancer

## Interventions

- **DRUG:** rhTSH stimulation
- **DRUG:** I131
- **OTHER:** Follow up

## Key facts

- **NCT ID:** NCT01837745
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2013-05-13
- **Primary completion:** 2022-04-01
- **Final completion:** 2030-01-01
- **Target enrollment:** 776 (ACTUAL)
- **Last updated:** 2023-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01837745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01837745, "Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients?". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT01837745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*